28 jun: Bagmandspolitiet får rekordmange indberetninger om hvidvask - cit..
28 jun: Novo: Oralt Semaglutid fortsætter med at vise gode takter i nyt s..
28-06-2018 10:08:12

Oral semaglutide shows superior reductions in HbA1c and weight compared to sitagliptin in the long-term safety and efficacy trial, PIONEER 3

Relateret indhold
17 jan - 
Aktier/middag: Chr. Hansen vender på en tallerken i grø..
17 jan - 
Aktier/middag: Chr. Hansen vender på en tallerken i lys..
16 jan - 
Novo lægger ekstra insulin på lager i Storbritannien op..
Relateret debat
17 jan - 
Novo har længe været i gang med at trimme omkostningern..
17 jan - 
Ja, jeg tror novo er ved at være ovre "sin dans på sted..
17 jan - 
Lad os håbe 🤞

Bagsværd, Denmark, 28 June 2018 - Novo Nordisk today announced the headline results from PIONEER 3, a phase 3a trial with oral semaglutide for the treatment of adults with type 2 diabetes. Oral semaglutide is an investigational GLP-1 analogue taken once daily as a tablet. The 78-week trial investigated the efficacy and long-term safety of 3, 7 and 14 mg oral semaglutide compared with 100 mg sitagliptin in 1,864 people with type 2 diabetes inadequately controlled with metformin, with or without sulfonylurea. The confirmatory endpoints were assessed after 26 weeks of treatment.

Two distinct statistical approaches to evaluating the effects of oral semaglutide were applied in the PIONEER 3 trial; a primary statistical approach[1] required by recent regulatory guidance evaluating the effect regardless of discontinuation of treatment and use of rescue medication, and a secondary statistical approach[2] describing the effect while on treatment and without use of rescue medication.

The trial achieved its primary objective according to the primary statistical approach by demonstrating statistically significant and superior reductions in HbA1c with oral semaglutide 7 and 14 mg compared to sitagliptin at week 26. Furthermore, people treated with oral semaglutide 7 and 14 mg achieved statistically significant and superior reductions in body weight compared to sitagliptin at week 26.

When applying the secondary statistical approach for week 26 and week 78, respectively, people treated with 7 and 14 mg oral semaglutide experienced statistically significantly greater reductions in HbA1c of 1.1% and 0.7% with 7 mg oral semaglutide, 1.4% and 1.1% with 14 mg oral semaglutide compared to 0.8% and 0.4% with sitagliptin.  Reductions in HbA1c with 3 mg oral semaglutide at 26 and 78 weeks were 0.5% and 0.3%, respectively, and the reduction was statistically significantly less than sitagliptin at 26 week, but was not statistically different at week 78. Reductions in body weight from baseline were statistically significantly greater with 3, 7 and 14 mg oral semaglutide at week 26 and 78, respectively, with reductions of 1.2 and 1.9 kg for 3 mg oral semaglutide, 2.2 and 2.7 kg for 7 mg oral semaglutide and 3.3 and 3.5 kg for 14 mg oral semaglutide compared to 0.7 and 1.1 kg with sitagliptin.

In this 78-week trial, oral semaglutide was well-tolerated and with a profile consistent with GLP-1-based therapy. The most common adverse event for oral semaglutide was mild to moderate nausea, which diminished over time. In PIONEER 3, 7-15% of people treated with oral semaglutide experienced nausea, compared to 7% of people treated with sitagliptin. The proportion of people who discontinued treatment due to adverse events was 6-12% for people treated with oral semaglutide compared to 5% with sitagliptin.

"With the results from the PIONEER 3 trial, we have shown that the two highest doses of oral semaglutide achieved superior improvements in glycaemic control and body weight compared to sitagliptin with a favourable safety profile consistent with GLP-1-based therapy" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "Furthermore, PIONEER 3 is an important trial, as it demonstrates long-term safety and efficacy of oral semaglutide"

About PIONEER 3 and the PIONEER clinical trial programme

PIONEER 3 was a 78-week, randomised, double-blind, double-dummy, active-controlled, parallel-group, multicentre, multinational trial with four arms comparing the efficacy and safety of 3, 7 and 14 mg oral semaglutide with 100 mg sitagliptin in people with type 2 diabetes inadequately controlled with metformin, with or without sulfonylurea. PIONEER 3 randomised 1,864 people in a 1:1:1:1 manner to receive either a dose of oral semaglutide 3, 7 and 14 mg or 100 mg sitagliptin once daily. The primary endpoint was change from baseline to week 26 in HbA1c. Key secondary endpoints included change in HbA1c and body weight from baseline to week 78.

The PIONEER phase 3a clinical development programme for oral semaglutide is a global development programme with enrolment of 8,845 people with type 2 diabetes across 10 clinical trials, which are all expected to complete in 2018.

Further information

Media:

 

 

Mette Kruse Danielsen +45 3079 3883

mkd@novonordisk.com

Ken Inchausti (US) +1 609 786 8316

kiau@novonordisk.com

 

 

 

Investors:

 

 
Peter Hugreffe Ankersen +45 3075 9085

phak@novonordisk.com

Anders Mikkelsen +45 3079 4461

armk@novonordisk.com

Christina Kjær +45 3079 3009

cnje@novonordisk.com

                


[1]

Treatment policy estimand approach: treatment effect regardless of discontinuation of treatment or initiation of rescue medication (analysed by pattern mixture model using multiple imputations to handle missing data with an analysis of covariance (ANCOVA)).

[2]

Hypothetical estimand approach: treatment effect while on treatment without use of rescue medication (analysed by Mixed Models for Repeated Measurements (MMRM)). Similar statistical methodology as applied in the SUSTAIN programme for subcutaneous semaglutide.

Company announcement No 53 / 2017

PR180628_PIONEER_3_UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Globenewswire

Vedhæftet fil: PR180628_PIONEER_3_UK.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13 jan
NOVO-B
Har hørt en lille fugl synge om, at en korrektion (måske) er ved at være afviklet efter 20% fald i f..
15
14 jan
NOVO-B
Så er det på tide at stoppe diskussionerne og blot forholde sig til fakta. Denne guideline forklarer..
5
13 jan
NOVO-B
Lad være med at lytte efter fuglene. De synger ofte falsk. Der skal nok komme en korrektion, men hvo..
5
13 jan
NOVO-B
Husk nu på at banker og børsmægler er afhænge af at folk sælger aktier og helst går i panik ellers t..
4
14 jan
NOVO-B
Det havde med Zealands pipeline, at gøre, de 3 års debat weee henviste til.   En forventet nutidsvær..
3
13 jan
NOVO-B
Korrektion eller ej. Bliver max spændende om Novo i.f.m. årsregnskabet kan overraske positivt og om ..
3
13 jan
NOVO-B
@DGL77 Er det en pingvin du har lyttet til? 🐧🦆🦃 Hvad er dit eget bud mht Apis-tyren? 🐂
3
11 jan
NOVO-B
Novo og Sanofi følger som ventet de øvrige selskabers prisstigning.   Bortset fra, at alt skal være ..
3
14 jan
NOVO-B
TEVA 'truslen' i Medwatch, er formuleret som om TEVA nu har besluttet sig GLP-1 og bliver farlig for..
2
16 jan
NOVO-B
Amarin trenden viser at et evt. sats kan hentes længere nede ;)   https://invst.ly/9sr59  
1

DSV/Exane: Anbefalingen løftes efter købstilbud på rival

17-01-2019 10:12:08
Transport- og logistikkoncernen DSV har fået løftet anbefalingen til "outperform" fra "neutral" af Exane BNP Paribas.Kursmålet lyder fortsat på 600 kr., viser data fra Bloomberg News.Onsdag kom det frem, at DSV har budt rundt regnet 26,5 mia. kr. for den schweiziske transportkoncern Panalpina, hvor bestyrelsen nu overvejer mulighederne.DSV-aktien falder 0,5 pct. til 497 kr. torsdag efter en stigni..

Aktier/tendens: Chr. Hansen i fokus efter regnskabsskuffelse

17-01-2019 08:32:35
Chr. Hansen kommer i fokus fra aktieåbningen herhjemme torsdag, efter at ingredienskoncernen fra morgenstunden har præsenteret tal for første kvartal af det forskudte regnskabsår 2018/19. Både omsætningen og indtjeningen ramte under analytikernes forventninger.Overordnet ventes markederne i Europa torsdag at åbne med en lille pil ned, efter historien om, at de amerikanske myndigheder efterforsker ..

MHI Vestas-rival sender 10 MW-mølle på markedet - NY

16-01-2019 09:26:16
MHI Vestas' største rival, Siemens Gamesa, er nu klar til at følge i hælene på det dansk-japanske selskab med en havvindmølle med en kapacitet på 10 megawatt (MW).Onsdag morgen løfter selskabet sløret for nylanceringen, som vil blive installeret som prototype i år og være klar til installation i stor stil i 2022.Med lanceringen følger Siemens Gamesa i hælene på MHI Vestas, der i september 2018 opg..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Pandora/Sydbank: Signet-tal er skidt nyt - men ingen stor overraskelse
2
Stor britisk bagerkæde har afdækket massiv svindel
3
GE rejser kæmpemølle i Holland til sommer
4
Aktier/tendens: Chr. Hansen i fokus efter regnskabsskuffelse
5
Aktier/middag: Chr. Hansen vender på en tallerken i grønt marked - NY

Relaterede aktiekurser

Novo Nordisk B A/S 310,70 1,0% Stigning i aktiekurs

Køb- og salgssignaler

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. januar 2019 03:26:34
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190108.3 - EUROWEB5 - 2019-01-18 03:26:34 - 2019-01-18 03:26:34 - 1 - Website: OKAY